Pharma BD Deal Intelligence
GSK acquired Human Genome Sciences for $3B for lupus and diabetes treatments.
GSK finalized its Human Genome Sciences acquisition for $14.25 per share in cash, completing a deal that brings Benlysta royalty savings and an expanded…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
GSK acquired Human Genome Sciences for $3B for lupus and diabetes treatments.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GSK plc / Human Genome Sciences (this deal) | 2012 | $3.6B | 70 |
| GSK plc / SmithKline Beecham | 2000 | $12.0B | 79 |
| GSK plc / Pfizer Inc. | 2018 | $0.0M | 77 |
| GSK plc / Novartis AG | 2014 | $16.0B | 76 |
| GSK plc / Hansoh Pharmaceutical Group Co. Ltd. | 2023 | $1.7B | 74 |
| GSK plc / Nuvalent, Inc. | 2026 | $10.6B | 70 |
| GSK plc / Sierra Oncology Inc. | 2022 | $1.9B | 70 |
← Browse all deals · How we score deals
More: 2012 deals · GSK plc deals · Immunology deals